TRPC4/TRPC5 channels mediate adverse reaction to the cancer cell cytotoxic agent (-)-Englerin A by Cheung, SY et al.
Oncotarget29634www.oncotarget.com
TRPC4/TRPC5 channels mediate adverse reaction to the cancer 
cell cytotoxic agent (-)-Englerin A
Sin Ying Cheung1, Matthias Henrot2, Mohammad Al-Saad3, Matthias Baumann4, 
Heiko Muller4, Anke Unger4, Hussein N. Rubaiy1, Ilka Mathar5, Klaus Dinkel4, Peter 
Nussbaumer4, Bert Klebl4, Marc Freichel5, Baptiste Rode1, Sebastian Trainor1, 
Steven J. Clapcote3, Mathias Christmann2, Herbert Waldmann6,7, Syed Khawar 
Abbas1, David J. Beech1 and Naveen S. Vasudev1
1School of Medicine, University of Leeds, Leeds, LS2 9JT, England, UK
2Institute of Chemistry and Biochemistry, Freie Universität Berlin, 14195 Berlin, Germany
3School of Biomedical Sciences, University of Leeds, Leeds, LS2 9JT, UK
4Lead Discovery Center GmbH, D-44227 Dortmund, Germany
5Institute of Pharmacology, Universität Heidelberg, D-69120 Heidelberg, Germany
6Max-Planck-Institut für Molekulare Physiologie, D-44227 Dortmund, Germany
7Technische Universität Dortmund, Fakultät für Chemie und Chemische Biologie, D-44227 Dortmund, Germany
Correspondence to: Naveen S. Vasudev, email: n.vasudev@leeds.ac.uk
David J. Beech, email: D.J.Beech@leeds.ac.uk
Keywords: TRPC4 channels; TRPC5 channels; renal cancer; breast cancer; Ewing’s sarcoma
Received: September 29, 2017    Accepted: May 01, 2018    Published: July 03, 2018
Copyright: Cheung et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 
3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and 
source are credited.
ABSTRACT
(-)-Englerin A (EA) is a natural product which has potent cytotoxic effects on 
renal cell carcinoma cells and other types of cancer cell but not non-cancer cells. 
Although selectively cytotoxic to cancer cells, adverse reaction in mice and rats 
has been suggested. EA is a remarkably potent activator of ion channels formed by 
Transient Receptor Potential Canonical 4 and 5 proteins (TRPC4 and TRPC5) and TRPC4 
is essential for EA-mediated cancer cell cytotoxicity. Here we specifically investigated 
the relevance of TRPC4 and TRPC5 to the adverse reaction. Injection of EA (2 mg.kg-1 
i.p.) adversely affected mice for about 1 hour, manifesting as a marked reduction in 
locomotor activity, after which they fully recovered. TRPC4 and TRPC5 single knockout 
mice were partially protected and double knockout mice fully protected. TRPC4/
TRPC5 double knockout mice were also protected against intravenous injection of EA. 
Importance of TRPC4/TRPC5 channels was further suggested by pre-administration 
of Compound 31 (Pico145), a potent and selective small-molecule inhibitor of TRPC4/
TRPC5 channels which did not cause adverse reaction itself but prevented adverse 
reaction to EA. EA was detected in the plasma but not the brain and so peripheral 
mechanisms were implicated but not identified. The data confirm the existence of 
adverse reaction to EA in mice and suggest that it depends on a combination of 
TRPC4 and TRPC5 which therefore overlaps partially with TRPC4-dependent cancer 
cell cytotoxicity. The underlying nature of the observed adverse reaction to EA, as 
a consequence of TRPC4/TRPC5 channel activation, remains unclear and warrants 
further investigation.
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INTRODUCTION
Three of the most challenging cancers are renal cell 
carcinoma, triple negative breast cancer and Ewing’s sarcoma 
[1–4]. Therefore it has been interesting to see the recent 
discovery of (-)-Englerin A (EA), a natural sesquiterpene 
from the Phyllanthus engleri plant, as a potent cytotoxic 
agent against some cancer cell lines developed from patients 
with these cancers [5–9]. Cancer cell lines from other types 
of cancer are also killed by EA whereas other cancer cells are 
resistant, as are non-cancerous cells [6–8]. EA may therefore 
be a starting point for developing new types of agent which 
are effective against certain types of cancer for which 
innovative treatment strategies are urgently needed.
If EA is to be the basis for therapeutic drug 
discovery, it is important to know the underlying 
molecular mechanisms by which it achieves cancer cell-
specific cytotoxicity. Surprisingly, EA was found to be a 
remarkably efficacious agonist of the TRPC4 and TRPC5 
ion channels [7, 8, 10]. It has nanomolar potency at these 
channels and is apparently directly-acting and specific [7, 
8]. Importantly, the cytotoxicity of EA against cancer cells 
is strongly TRPC4-dependent [7, 10]. The mechanism of 
cytotoxicity depends on Na+ entry through the TRPC4 
channels [10]. Consistent with this mechanism, the effect 
of EA is potentiated by ouabain, an inhibitor of Na+ K+-
ATPase, suggesting that vulnerability to EA-induced 
cytotoxicity depends on a combination of excess sustained 
Na+ entry (through TRPC4 channels) and insufficient 
compensation by Na+ extrusion (by Na+ K+-ATPase) [10]. 
EA activates TRPC5 channels [8] but it has been suggested 
that this channel might only rarely be relevant to cancer 
cell cytotoxicity [7], although the topic is worthy of further 
investigation because of the suggested importance of 
TRPC5 in chemotherapy-resistant breast cancer [11]. EA 
might have other targets and a prominent suggestion in this 
regard is the protein kinase C, PKCθ [9]. Whether the PKCθ 
mechanism is related to TRPC4 channels is unknown.
Despite the promising mechanistic findings and lack of 
effect of EA on non-cancer cells in culture, a challenge with 
EA might be adverse effect in vivo: Although an initial study 
used EA successfully in vivo in mice to inhibit xenograft 
tumor growth, without notable adverse effect, a subsequent 
study suggested unacceptable toxicity [7, 9]. A key question 
in this situation is whether any observed adverse effects of 
EA represent an on- or off-target event. Here we investigated 
the possibility for adverse effect in vivo in mice and whether 
it involves the TRPC4/TRPC5 channels.
Figure 1: Adverse reaction to (-)-Englerin A (EA) in wild type mice. (A) Representative track plots generated from the Open 
Field Test on mice administered with Vehicle (Veh.), 1 mg.kg-1 EA or 2 mg.kg-1 EA. (B) Total distance travelled and, (C) total freezing 
time of mice administered Vehicle (Veh.), 1 mg.kg-1 EA or 2 mg.kg-1 EA (n=3 per group). (D) Examples for individual mice of cumulative 
distance travelled plotted against time for Vehicle (Veh.) and 2 mg.kg-1 EA injection. Representative of n=9 each.
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RESULTS
EA induces adverse reaction
Previous study suggested that intraperitoneal 
injection of EA in nude mice at >1 mg.kg-1 was not 
tolerated [7]. Using a similar formulation we investigated 
EA at 1 or 2 mg.kg-1 in wild type C57BL/6 mice. A rapid 
effect on locomotor activity was observed, which we 
quantified using the Open Field Test (Figure 1A). EA 2 
mg.kg-1 had a more consistent effect than 1 mg.kg-1 but 
both doses severely reduced the total distance travelled 
and strongly increased the freezing time (Figure 1A-
1C) (Supplementary Video). The Open Field Test 
illustrated strong negative effect on mice for about 1 
hour, followed by recovery (Figure 1D). No mice died 
at these doses, administered via the intraperitoneal route. 
Pilot studies suggested that a higher dose of 5 mg.kg-1 
was poorly tolerated and so further studies at this dose 
were considered unethical. The data suggest that C57BL/6 
mice have negative reaction to EA, which manifests as a 
transient reduction in locomotor activity.
Knockout of TRPC4 or TRPC5 partially protects 
against EA
To test whether TRPC4 is involved in the adverse 
effect of EA, we next used mice with genetically disrupted 
Trpc4 gene. In these mice there was absence of TRPC4 
protein (Figure 2A). In vehicle-injected TRPC4 knockout 
mice (C4KO), distance travelled and freezing times were 
normal (Figure 2B-2D cf Figure 1A-1C). In contrast, the 
effects of EA on distance travelled and freezing times 
were significantly attenuated (Figure 2B-2D). The data 
suggested that TRPC4 knockout partially protected against 
the adverse effect of EA.
We similarly studied TRPC5 knockout mice 
(C5KO). Absence of TRPC5 protein was confirmed 
(Figure 3A). As with TRPC4 knockouts, vehicle-
injected C5KO mice behaved normally (Figure 3B-3D). 
In contrast, the effects of EA on distance travelled and 
freezing times were significantly attenuated (Figure 3B-
3D). The data suggested that TRPC5 knockout partially 
protected against the adverse effect of EA.
The data suggested that TRPC4 and TRPC5 both 
contributed to the adverse effect of EA. Importantly, 
substantial adverse effect of EA remained in both knockout 
mice, suggesting that adverse effect did not depend on 
TRPC4 or TRPC5 alone.
Knockout of TRPC4 and TRPC5 fully protects 
against EA
Because EA activates both TRPC4 and TRPC5 we 
hypothesized that both proteins mediate a similar adverse 
effect of EA or that one protein compensates when the 
other is disrupted. This could explain why the single 
knockouts only partially protected against EA. Therefore, 
we generated TRPC4 and TRPC5 double knockout mice 
(Double KOs). In vehicle-injected Double KOs, the 
distance travelled was less than in wild type mice but 
freezing times were similar (Figure 4A-4C). Despite 
this difference in baseline for distance travelled, it was 
striking that there was complete protection against EA 
(Figure 4A-4C). The data suggested that adverse reaction 
to EA depends completely on a combination of TRPC4 
and TRPC5. No adverse reaction was observed in Double 
KO mice.
Previous study has suggested a particularly severe 
reaction to intravenous injection of EA [7]. Such an effect 
might involve a mechanism which is different from that 
observed in response to intraperitoneal injection. We 
therefore administered EA intravenously in wild type 
(WT) mice and TRPC4 and TRPC5 double knockout 
mice (Double KOs). EA 2 mg.kg-1 caused rapid lethality 
(n=1) and so studies with this dose were discontinued 
and lower doses were explored. At 0.02 mg.kg-1 EA, 
wild type mice showed mild signs of physiological 
distress including increased grooming and spontaneous 
movement within the cage (n=3). In contrast, Double 
KOs exhibited no response to 0.02 mg.kg-1 EA, behaving 
apparently normally (n=3). At 0.2 mg.kg-1 EA there was 
rapid lethality in wildtype mice, whereas in Double KOs 
there were signs of palpitation which then subsided within 
30 s and mice recovered fully with no obvious symptoms 
thereafter (n=3). The data suggested that adverse reaction 
to intravenous EA depends on TRPC4 and/or TRPC5.
Small-molecule inhibition of TRPC4/TRPC5 
channels fully protects against EA
To investigate the role of TRPC4/TRPC5 channels 
independently of the genetic approach we took advantage 
of a newly-identified potent and specific inhibitor of 
these ion channels called Compound 31 (C31), a.k.a. 
Pico145 [12]. Importantly, pre-administration of C31 
fully protected against the adverse effect of EA injected 
intraperitoneally, such that distance travelled and freezing 
times were similar to those of mice without EA injection 
(Figure 5A-5C cf Figure 1A-1C). The data supported the 
hypothesis that TRPC4/TRPC5 channels are essential for 
adverse response to EA.
EA is peripherally restricted
TRPC4 and TRPC5 channels are expressed in the 
central nervous system where their activation has been 
associated with epilepsy and fear [13–15]. We therefore 
investigated whether EA is distributed to the brain. EA 5 
mg.kg-1 was injected intraperitoneally under anaesthesia 
in nude mice. Its concentration and that of its metabolite 
Englerin B (EB) were measured in plasma and brain 5 
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and 10 min after injection. EA was detectable in plasma 
but not brain whereas EB was detectable in both, albeit at 
lower concentration in brain (Figure 6). Intriguingly, EA 
5 mg.kg-1 was not lethal to these anaesthetized mice. The 
data suggested the EA is peripherally restricted and that 
the adverse reaction is likely to be mediated peripherally.
DISCUSSION
This study supports the existence of adverse 
reaction to EA in mice and reveals the essential role of 
the combination of TRPC4 and TRPC5 in the adverse 
reaction. The reaction is dose-dependent and lethal at 
high dose. At the dose of 2 mg.kg-1 the reaction is severe, 
manifesting as a significant reduction in locomotor 
activity, but not lethal, with mice gradually recovering to 
an apparently normal state. Strikingly, knockout of TRPC4 
or TRPC5 and small-molecule blockade of the channels 
had no obvious effect on their own but knockout of either 
protein partially protected against this reaction to EA and 
double knockout, or small-molecule blockade, completely 
protected against EA. EA did not distribute significantly 
to the brain but was detected in plasma, suggesting a 
peripheral mechanism underlying the adverse reaction. 
The identity of this mechanism is unknown, other than 
that TRPC4 and TRPC5 are critical.
Anti-cancer cell effects of EA are critically-
dependent on TRPC4 [7, 8]. Therefore, our data indicate 
that the adverse effect of EA is on target (mediated by 
the same mechanism as the anti-cancer cell effect). Our 
studies and those of other groups have not supported the 
idea of EA having a high-affinity target other than TRPC4 
and TRPC5 [7, 8]. The suggested effect of EA on CaV1.2 
voltage-gated Ca2+ channels reflects a low-affinity target 
Figure 2: Partial protection by TRPC4 knockout. (A) Western blot data for total brain proteins from wild type (WT) and TRPC4 
knockout (C4KO) mice. Using anti-TRPC4 antibody (upper gel) and anti-GAPDH (lower gel, loading control). Each lane is protein for a 
different mouse. There were 4 mice in the WT group and 4 mice in the C4KO group. (B-D) Data generated for wild type (WT) and TRPC4 
knockout mice (TRPC4 KO) in the Open Field Test. (B) Representative track plots, (C) total distance travelled and (D) total freezing time 
after intraperitoneal injection of vehicle, 1 mg.kg-1 EA or 2 mg.kg-1 EA (n=3 mice per group).
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in the middle micromolar concentration range [16], which 
is about 3 orders of magnitude worse than the potency at 
TRPC4 or TRPC5 channels [7, 8].
The adverse reaction induced by EA was sustained 
for about 1 hour, after which the mice began to recover. 
The reason for the transient nature of the effect is likely 
to be metabolic instability of EA in rodents – probably 
its conversion to the metabolite Englerin B (EB) which is 
inactive as an agonist at TRPC4 and TRPC5 channels [7]. 
Therefore, if a metabolically stable EA analogue can be 
discovered with retained potent agonistic action at TRPC4 
and TRPC5 channels we anticipate that it would cause 
even more severe adverse reaction.
Our findings add to prior knowledge [17] by 
showing that Compound 31 (a.k.a. Pico145) is an inhibitor 
of TRPC4 and TRPC5 channels in vivo. On its own, C31 
appeared to be without adverse effect, although we only 
made visual observations of the mice for one hour post-
administration before injecting EA. More recently, an 
anxiolytic and anti-depressant effect in mice of HC-070, a 
highly similar compound to C31 that also inhibits TRPC4 
and TRPC5 channels with high potency and selectivity, 
has been described [18].
The focus of our study was to examine the role 
of TRPC4 and TRPC5 channels in mediating adverse 
reaction to EA. The underlying nature of the adverse 
Figure 3: Partial protection by TRPC5 knockout. (A) Western blot data for total brain proteins from wild type (WT) and TRPC5 
knockout (C5KO) mice. Using anti-TRPC5 antibody (upper gel) and anti-GAPDH (lower gel, loading control). Each lane is total protein for 
a different mouse. There were 3 mice in the WT group and 3 mice in the C5KO group. (B-D) Data generated for wild type (WT) and TRPC5 
knockout mice (TRPC5 KO) in the Open Field Test. (B) Representative track plots, (C) total distance travelled and (D) total freezing time 
after intraperitoneal injection of vehicle, 1 mg.kg-1 EA or 2 mg.kg-1 EA (n=3 mice per group).
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reaction to EA in vivo, as a consequence of activating 
TRPC4/5 channels peripherally, remains uncertain but 
manifests as reduction in locomotor activity. A similar 
effect was reported after subcutaneous injection of 3 
mg.kg-1 EA in nude mice [7]. Since the cytotoxic effects 
of EA are thought to be cancer cell specific, we do not 
believe direct cytotoxicity to be a likely mechanism but 
cannot exclude it. Labored breathing, possibly secondary 
to pulmonary edema, and elevations or occasional 
reductions of blood pressure, without effect on cardiac 
contractility, has been suggested after subcutaneous and 
intravenous injection of EA, respectively, in nude mice 
[7]. Whilst we did not observe labored breathing in treated 
mice, it is possible that alterations in vascular or cardiac 
function were responsible for the observed reaction. 
Roles of TRPC4 and TRPC5 located to the central 
nervous system [14, 15] seem unlikely in light of the 
exclusive peripheral distribution of EA. Skeletal muscle 
weakness could be an explanation but we noted that the 
mice remained on their feet and the thorax palpitated, 
so weak muscle tone is unlikely. Gastrointestinal spasm 
may contribute because of the important role of TRPC4 
channels in contractile function of the intestines [19]. 
These are but a few possibilities. The broad expression of 
TRPC4 and TRPC5 will make it challenging to identify 
the mechanism of EA toxicity. Furthermore, it remains 
unclear if the mechanism causing the transient reaction 
observed in our study is directly related to lethality or if 
there are two mechanistically unrelated effects.
Novel cancer therapeutics are urgently required 
in the clinic. Renal cell carcinoma, for example, is 
resistant to traditional cytotoxic chemotherapies and 
remains incurable in patients with metastatic disease. 
VEGF-receptor targeted tyrosine kinase inhibitors form 
a mainstay of current treatment, although on-target 
side-effects such as diarrhea and hypertension are well 
recognized. In the majority of patients, such toxicity can 
be managed safely, with an acceptable risk/benefit ratio 
Figure 4: Full protection by TRPC4 and TRPC5 double knockout. (A) Representative track plots from data generated for wild 
type (WT) and TRPC4 and TRPC5 double knockout mice (Double KO) in the Open Field Test. (B) Total distance travelled and, (C) Total 
freezing time after intraperitoneal injection of vehicle, 1 mg.kg-1 EA or 2 mg.kg-1 EA (n=3 mice per group).
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achieved. Given that the in vivo anti-cancer activity of 
EA remains to be clearly established, together with the 
rapidity, severity and, as yet, poorly defined nature of the 
toxicity associated with EA, significant concerns around 
the potential of EA analogues as anti-cancer agents in the 
clinic must remain.
Figure 5: Full protection by a small-molecule inhibitor of TRPC4/TRPC5 channels. (A) Representative track plots from the 
Open Field Test using wild type C57BL/6 mice. Mice were orally administered 1 mg.kg-1 Compound 31 (C31) or its vehicle 1 hr prior to 
intraperitoneal injection of 2 mg.kg-1 EA. (B) Total distance travelled and, (C) Total freezing time after intraperitoneal injection of vehicle 
or EA (n=3 mice per group).
Figure 6: EA distributes peripherally and not to the brain. Analysis of the concentration of EA and its metabolite Englerin B (EB) 
in plasma and brain of nude mice 5 and 10 min after intraperitoneal injection of EA 5 mg.kg-1 (n=3 mice). EA was not detected in the brain.
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We used the minimum number of animals and did 
not exceed dosing at 2 mg.kg-1 in conscious mice because 
of ethical constraints. The study was not designed to 
explore the effects of TRPC4 and TRPC5 knockouts on 
murine behavior. The data obtained with these knockouts 
in the absence of EA administration were nevertheless 
suggestive that neither TRPC4 nor TRPC5 alone was 
important for the parameters measured by the Open Field 
Test. However, the absence of both TRPC4 and TRPC5 
reduced the times in the center and intermediate zones of 
the field as well as the total distance travelled.
In conclusion, the study importantly confirms 
adverse reaction to EA in mice and shows clearly that the 
mechanism requires both TRPC4 and TRPC5. Because 
the most common cancer cell cytotoxic effect of EA 
requires TRPC4 and not TRPC5, the study suggests 
partial overlap of the potential anti-cancer effect and 
the adverse reaction of EA. A TRPC4-specific agonist, 
should it be developed, might therefore be an approach 
for achieving an anti-cancer effect with tolerable toxicity, 
but careful dose-dependency studies would be needed with 
a stable analogue of the agonist before clinical trials could 
reasonably be considered.
MATERIALS AND METHODS
Animals
Trpc4 gene-disrupted (knockout) mice on the 
C57BL/6J background (B6.129P2-Trpc4tm1Dgen/H) were 
generated by Deltagen Inc. and supplied by the Medical 
Research Council Harwell, UK. The sequence spanning 
base 1272 to base 1330 of the TRPC4 gene was deleted, 
where it was inserted with a Lac-Z neo cassette to create 
a detectable mutation in the TRPC4 knockout mice. 
Trpc5 gene-disrupted (knockout) C57BL/6 mice were 
generated as part of the International Mouse Phenotyping 
Consortium (IMPC); they were based on Trpc5 gene-
targeted ES cells originally created by the Knockout 
Mouse Project (KOMP) (Trpc5tm1b(KOMP)Wtsi) and 
provided by Riken BRC, Japan. Mice were intercrossed to 
generate homozygous single and double knockouts. Mice 
were weaned at 3 weeks of age and 2-5 mice were housed 
in the same cage with same-sex littermates under a 12 hour 
light/dark cycle. Mice of either sex were used. The wild 
type mice were from the same line of the KO mice for 
experiments where the effect of EA was being compared 
between wild type and knock-out mice. For experiments 
using the C31 compound, the wild type mice were from 
the TRPC4 line. Wild type and knockout pairs were 
sex-matched. Food pellets and water were provided ad 
libitum. All procedures were approved by the University 
of Leeds Animal Welfare and Ethical Review Body and 
were conducted under a moderate protocol on a project 
licence issued by the competent authority of the United 
Kingdom. Englerin distribution studies were carried out 
at Synovo GmbH Tübingen using female athymic nude 
mice obtained from Taconic. All experimental procedures 
were approved by and conducted in accordance with 
the regulations of the local Animal Welfare Authorities 
(Tübingen Regional Council).
Open field test
Experiments were conducted largely as described 
previously [20]. Animals used were 6-8 weeks of age, sex-
matched for wild type and knockout pairs to be compared. 
Mice were placed into a 40 x 40 x 40 cm arena illuminated 
under standard white fluorescent ceiling lights at an 
intensity of ~200 lux. All experiments were recorded using 
a webcam attached to a tripod positioned above the arena, 
connected to the computer tracking software ANY-maze 
(Stoelting Co., USA). The tracking software divided the 
arena into three zones: Outer Zone (8 cm from the outer 
walls), Center Zone (6.4 cm2; 16% of the total area) and 
Intermediate Zone (the remaining area between the outer 
and center zone). The duration (time pressed, seconds) of 
rearing and grooming was manually measured.
Sample preparation for EA and Englerin B (EB)
EA and EB were extracted from plasma and tissue 
by protein precipitation using acetonitrile. Brain samples 
were homogenized in PBS prior to extraction. Filtrates 
were further diluted with mobile phase and analyzed 
using a Shimadzu Prominence UFLC system coupled to 
an ABSciex QTrap 5500 instrument. EA and EB were 
separated by gradient elution using an Agilent Poroshell 
EC 120 C18 column. Mobile phase A consisted of water 
containing 10 mM ammonium acetate, and mobile phase 
B consisted of acetonitrile containing 10 mM ammonium 
acetate with a flow rate of 1 ml.min-1. Ionization of EA 
and EB was achieved by electrospray ionization (ESI) 
in positive mode. Mass spectrometer parameters were 
optimized previously for both analytes. Concentrations of 
EA and EB were calculated by means of a standard curve 
using spiked biological sample matrix. Peak processing 
and curve fitting was performed using Analyst 1.6.2 
software from ABSciex.
Western blotting methods and antibodies
Tissues were homogenized in Radio-Immuno 
precipitation Assay (RIPA) buffer containing (in mM) 150 
NaCl, 20 Tris-base, 1 EGTA, 1 EDTA, 1% NP-40, 0.1% 
sodium dodecyl sulfate (SDS) and 1% sodium deoxylate, 
pH 7.6 (HCl). cOmplete™ protease inhibitor (Roche Life 
Science) was prepared in solution in accordance with the 
manufacturer’s instructions and added into RIPA before 
use. Western blotting was carried out under standard 
protocols with primary antibodies TRPC4 (1:200, 75-119, 
UC Davis/NIH Neuromab), and TRPC5 (1:200, 75-104, 
UC Davis/NIH Neuromab). GAPDH (1:4000, AM4300; 
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Ambion Life Technologies) was used as loading control. 
Subsequent to primary antibody incubation, secondary 
antibodies anti-rabbit-HRP (1:3000, 711-035-152, 
Jackson ImmunoResearch) and anti-mouse-HRP (1:3000, 
715-035-150, Jackson ImmunoResearch) were used. 
Chemiluminescence of detected proteins were visualized 
using SuperSignal® West Femto Maximum Sensitivity 
Substrate (Thermo Fisher Scientific).
Chemicals
(-)-Englerin A (EA) was supplied by Phytolab 
GmbH. The stock solution was made at 10 mg.ml-1 in the 
Novartis approved ‘standard acceptable vehicle guidance 
for all in-life pre-clinical evaluations’ [7] containing 5% 
ethanol, 10% polyethylene glycol 300 (Sigma Aldrich), 5% 
cremophor EL (Merck Chemicals Ltd), and 80% PBS. The 
stock solution was sonicated for 10 min to dissolve EA and 
filtered through a 0.22 μm filter prior to further dilution 
and injection. For oral administration into mice by gavage, 
Compound 31 was dissolved in 0.5% methylcellulose, 
viscosity 400 cP (Thermo Fisher Scientific) and PBS. 
Compound 31 (C31, a.k.a. Pico145) was synthesized as 
previously described [12]. Buprenorphine Hydrochloride 
was Buprenex® and Carprofen was Rimadyl® diluted in 
PBS for subcutaneous injection.
Data analysis
Data are presented as mean ± SEM. n represents 
the number of independent experiments (e.g. mice). 
Comparisons of 2 data groups were by unpaired t-test. 
Multiple groups were compared by ANOVA with post 
hoc Bonferroni test. Values of statistical differences are 
provided in the figures. Data were analyzed using Origin 
software (OriginLab, Northampton, MA, USA).
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